Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2581 to 2595 of 8903 results

  1. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]

    Awaiting development Reference number: GID-TA11325 Expected publication date: TBC

  2. Upadacitinib for treating giant cell arteritis [ID6299]

    In development Reference number: GID-TA11330 Expected publication date: TBC

  3. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain

    Awaiting development Reference number: GID-HTG10168 Expected publication date: TBC

  4. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development Reference number: GID-TA11058 Expected publication date: TBC

  5. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  18 November 2026

  6. Ectopic pregnancy and miscarriage: diagnosis and initial management (update)

    In development Reference number: GID-NG10444 Expected publication date:  06 May 2026

  7. Ectopic pregnancy and miscarriage: diagnosis and initial management (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 17 February 2026.

  8. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

  9. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    In development Reference number: GID-TA11130 Expected publication date: TBC

  10. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897]

    In development Reference number: GID-TA11437 Expected publication date: TBC

  11. Asunercept for treating glioblastoma [ID1301]

    In development Reference number: GID-TA10227 Expected publication date: TBC

  12. Deuruxolitinib for treating severe alopecia areata [ID6597]

    In development Reference number: GID-TA11804 Expected publication date:  08 October 2026

  13. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]

    In development Reference number: GID-TA11636 Expected publication date:  26 August 2026

  14. Deutetrabenazine for treating tardive dyskinesia [ID6550]

    In development Reference number: GID-TA11718 Expected publication date: TBC

  15. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]

    In development Reference number: GID-TA11564 Expected publication date:  08 July 2026